New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
05:19 EDTLGND, TGTXLigand signs license agreement with TG Therapeutics for IRAK-4
Ligand Pharmaceuticals (LGND) announced the signing of a license agreement with TG Therapeutics (TGTX) for the development and commercialization of Ligandís Interleukin-1 Receptor Associated Kinase-4 inhibitors. The IRAK-4 program is in preclinical development for potential use in certain cancers and autoimmune diseases. Under the terms of the agreement, Ligand is entitled to receive 125,000 shares of TG Therapeutics common stock, valued at approximately $1M at date of signing, and is eligible to receive $207M in potential milestone payments. Ligand is also eligible to receive tiered royalties of 6% to 9.5% on future net sales of licensed products containing patented IRAK-4 inhibitors.
News For LGND;TGTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 26, 2014
08:31 EDTLGNDLigand, Merck receive approval for NOXAFIL
Subscribe for More Information
September 25, 2014
05:57 EDTTGTXTG Therapeutics price target raised to $22 from $19 at Brean Capital
Brean Capital raised its price target for TG Therapeutics shares to $22 after the company acquired the rights to TGR-1202 from Rhizen Pharmaceuticals. The firm keeps a Buy rating on the stock.
September 23, 2014
07:34 EDTTGTXTG Therapeutics announces exercise of license option for TGR-1202
TG Therapeutics announced that it has exercised its option to license the global rights to TGR-1202, the company's novel, next generation PI3K-delta inhibitor from Rhizen Pharmaceuticals, S A. The company and Rhizen have to date been jointly developing TGR-1202 in a 50:50 joint venture. Given the successful development of TGR-1202, TG Therapeutics elected an early exercise of the company's license option. In exchange for the global license, Rhizen will receive a one-time, upfront cash payment of $4M and approximately 370,000 shares of TG Therapeutics' common stock. TG Therapeutics will receive exclusive worldwide rights, excluding India, for the development and commercialization of TGR-1202 for all indications. Rhizen will be eligible to receive regulatory filing, approval and sales based milestones in the aggregate of approximately $240M, and tiered royalties based on net sales.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use